BioScrip Inc. (BIOS) Jumps 6.86% on December 23

Equities Staff |

BioScrip Inc. (BIOS) was among the biggest gainers on the Russell 2000 for Wednesday December 23 as the stock popped 6.86% to $1.64, representing a gain of $0.105 per share. Some 1.7 million shares traded hands on 5,879 trades, compared with an average daily volume of 1.12 million shares out of a total float of 68.75 million. The stock opened at $1.52 and traded with an intraday range of $1.76 to $1.49.

After today's gains, BioScrip Inc. reached a market cap of $112.4 million. BioScrip Inc. has had a trading range between $7.01 and $1.30 over the last year, and it had a 50-day SMA of $2.05 and a 200-day SMA of $3.05.

BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc. is based out of Elmsford, NY and has some 2,490 employees. Its CEO is Richard M. Smith.

For a complete fundamental analysis analysis of BioScrip Inc., check out’s Stock Valuation Analysis report for BIOS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…